CLSA President & CEO Mike Guerra was recently featured in the San Diego Union-Tribune commenting on employment trends in California’s life sciences sector.
“We all agree that drug prices are high, but a proposal before the Legislature would make that situation worse, even as it seeks to solve the problem.” Read more about AB 824 in CalMatters.
CLSA Board Member Wendye Robbins, MD, President & CEO of Blade Therapeutics, pens an op-ed in the San Francisco Chronicle, urging the Legislature to make key changes to Assembly Bill 824, priority legislation for CLSA that seeks to prohibit generic drug manufacturers from seeking patent settlement agreements.
Congress will return from its annual summer District Work period (“August Recess”) after Labor Day on Sept. 9. Looking ahead to legislative agenda for the fall, healthcare, and more specifically drug pricing, is expected to remain a critical issue for lawmakers to address.
CLSA was recently featured in the San Diego Business Journal regarding the expansion of its board of directors.
On Tuesday, August 20th, CLSA welcomed a host of lawmakers, legislative staffers, and other key stakeholders to a first of its kind medical device showcase reception in Sacramento.
CLSA leads industry efforts to halt Assembly Bill 1788, a bill that aims to prohibit the use of second-generation anticoagulant rodenticides (SGARs) throughout the state and also prohibit the use of first-generation anticoagulant (FGARs) rodenticides on state-owned property.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator Susan Rubio (D-Baldwin Park). We look forward to working with Senator Rubio and her team to advance policies that improve patient health and bring positive change for California patients and their families.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Assemblyman Tyler Diep (R-Westminster). We look forward to working with Assemblyman Diep and his team to advance policies that improve patient health and bring positive change for California patients and their families.
When Congress returns from the District Work period (“August recess”) in September, there will be only 10 legislative weeks remaining for Congress to take action to prevent the Medical Device Excise Tax from going back into effect on January 1, 2020. CLSA has worked closely with our membership, our national trade association partners, allied stakeholders and congressional champions to introduce the Protect Medical Innovation Act of 2019 (H.R. 2207), which would permanently repeal this innovation stifling tax.